发布于: 修改于: | 雪球 | 回复:8 | 喜欢:4 |
2022财报里写的是,and an additional $25 million milestone payment upon regulatory approval of efgartigimod by FDA in the U.S
Collaboration revenue for the fourth quarter and full year in 2023 was $32 million and $36 million, respectively, compared to $1 million and $10 million for the same periods in 2022. The increase is mainly related to the clinical development milestone argenx achieved with AbbVie following the dosing of the first patient in the Phase 2 trial for ABBV-151. Collaboration revenue for full year in 2023 also includes $1 million in royalty revenue from VYVGART sales in China.
那我没法说了,反正我核实过没有。[尴尬],中国区域23年一个适应症成功一个适应症上市,argenx这个显示没有收到那就是没有了。 难道后面日本ITP 过了,美国和中国都过不了,还得去付里程碑?也太不合逻辑了,各国监管逻辑都不一样,正常BD都不应该按照别的区域去执行。。不然全球多个授权,那简直乱成一锅粥了。